Safety and Tolerability of Bevacizumab Plus Paclitaxel vs. Bevacizumab Plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients With HER2-Negative Metastatic or Locally Recurrent Breast Cancer - A Multicenter, Randomized Phase III Trial.

Trial Profile

Safety and Tolerability of Bevacizumab Plus Paclitaxel vs. Bevacizumab Plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients With HER2-Negative Metastatic or Locally Recurrent Breast Cancer - A Multicenter, Randomized Phase III Trial.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Apr 2016 Planned End Date changed from 12 Feb 2016 to 1 Jun 2019.
    • 07 Jan 2016 Planned End Date changed from 1 Oct 2015 to 12 Feb 2016 as reported by ClinicalTrials.gov record.
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top